Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-21T17:50:49.507Z Has data issue: false hasContentIssue false
  • English
  • Français

Peripheral inflammation in mild cognitive impairment with possible and probable Lewy body disease and Alzheimer’s disease

Published online by Cambridge University Press:  11 March 2019

Eleanor King ,
John Tiernan O’Brien ,
Paul Donaghy Open the ORCID record for Paul Donaghy [Opens in a new window] ,
Christopher Morris ,
Nicola Barnett ,
Kirsty Olsen ,
Carmen Martin-Ruiz ,
John Paul Taylor  and
Alan J. Thomas
Eleanor King*
Affiliation:
Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
John Tiernan O’Brien
Affiliation:
Department of Psychiatry, University of Cambridge, Cambridge, UK
Paul Donaghy
Affiliation:
Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
Christopher Morris
Affiliation:
Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
Nicola Barnett
Affiliation:
Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
Kirsty Olsen
Affiliation:
Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
Carmen Martin-Ruiz
Affiliation:
Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
John Paul Taylor
Affiliation:
Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
Alan J. Thomas
Affiliation:
Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK
*
Correspondence should be addressed to: Eleanor King, Institute of Neuroscience, Biomedical Research Building, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, NE4 5PL, United Kingdom. Phone: 0191 208 1318; Fax: 0191 208 1301. Email: eleanor.king@newcastle.ac.uk.
Get access

Abstract

Objectives and design:

To Investigate the peripheral inflammatory profile in patients with mild cognitive impairment (MCI) from three subgroups – probable Lewy body disease (probable MCI-LB), possible Lewy body disease, and probable Alzheimer’s disease (probable MCI-AD) – as well as associations with clinical features.

Setting:

Memory clinics and dementia services.

Participants:

Patients were classified based on clinical symptoms as probable MCI-LB (n = 38), possible MCI-LB (n = 18), and probable MCI-AD (n = 21). Healthy comparison subjects were recruited (n = 20).

Measurements:

Ten cytokines were analyzed from plasma samples: interferon (IFN)-gamma, interleukin (IL)-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor necrosis factor (TNF)-alpha. C-reactive protein levels were investigated.

Results:

There was a higher level of IL-10, IL-1beta, IL-2, and IL-4 in MCI groups compared to the healthy comparison group (p < 0.0085). In exploratory analyses to understand these findings, the MC-AD group lower IL-1beta (p = 0.04), IL-2 (p = 0.009), and IL-4 (p = 0.012) were associated with increasing duration of memory symptoms, and in the probable MCI-LB group, lower levels of IL-1beta were associated with worsening motor severity (p = 0.002). In the possible MCI-LB, longer duration of memory symptoms was associated with lower levels of IL-1beta (p = 0.003) and IL-4 (p = 0.026).

Conclusion:

There is increased peripheral inflammation in patients with MCI compared to healthy comparison subjects regardless of the MCI subtype. These possible associations with clinical features are consistent with other work showing that inflammation is increased in early disease but require replication. Such findings have importance for timing of putative therapeutic strategies aimed at lowering inflammation.

Keywords

inflammationcytokinesCRPmild cognitive impairmentLewy body diseaseAlzheimer’s disease
Type
Original Research Article
Information
International Psychogeriatrics , Volume 31 , Issue 4: Issue Theme: Aging and Well-Being , April 2019 , pp. 551 - 560
Copyright
© International Psychogeriatric Association 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Albert, M. S. et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7, 270–279. doi: 10.1016/j.jalz.2011.03.008.CrossRefGoogle Scholar
Bettcher, B. M. et al. (2018). Cerebrospinal fluid and plasma levels of inflammation differentially relate to CNS markers of Alzheimer’s disease pathology and neuronal damage. Journal of Alzheimer’s Disease, 62, 385–397. doi: 10.3233/JAD-170602.CrossRefGoogle ScholarPubMed
Cooper, C., Sommerlad, A., Lyketsos, C. G. and Livingston, G. (2015). Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. American Journal of Psychiatry, 172, 323–334. doi: 10.1176/appi.ajp.2014.14070878.CrossRefGoogle ScholarPubMed
Cummings, J. L. et al. (1994). The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314. doi: 10.1212/WNL.44.12.2308.CrossRefGoogle ScholarPubMed
Dantzer, R. et al. (1999). Mechanisms of the behavioural effects of cytokines. Advances in Experimental Medicine and Biology, 461, 83–105. doi: 10.1007/b102345.CrossRefGoogle ScholarPubMed
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G. and De Vries, J. E. (1991). Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. Journal of Experimental Medicine, 174, 1209–1220. doi: 10.1084/jem.174.5.1209.CrossRefGoogle ScholarPubMed
Donaghy, P.C. et al. (2018). Neurophsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies. Psychological Medicine 24, 1–7. doi: 10.1017/S0033291717003956.Google Scholar
Dufek, M. et al. (2009). Serum inflammatory biomarkers in Parkinson’s disease. Parkinsonism and Related Disorders, 15, 318–320. doi: 10.1016/j.parkreldis.2008.05.014.CrossRefGoogle ScholarPubMed
Engelhart, M. J. et al. (2004). Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Archives of Neurology, 61, 668–672. doi: 10.1001/archneur.61.5.668.CrossRefGoogle ScholarPubMed
Furney, S. J. et al. (2011). Combinatorial markers of mild cognitive impairment conversion to Alzheimer’s disease – cytokines and MRI measures together predict disease progression. Journal of Alzheimer’s Disease, 26, 395–405. doi: 10.3233/JAD-2011-0044.CrossRefGoogle ScholarPubMed
Galimberti, D. et al. (2006). Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Archives of Neurology, 63, 538–543. doi: 10.1001/archneur.63.4.538.CrossRefGoogle ScholarPubMed
Goetz, C. G. et al. (2008). Movement Disorder Society–sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Disorders, 23, 2129–2170. doi: 10.1002/mds.v23:15.CrossRefGoogle ScholarPubMed
Heneka, M. T. et al. (2015). Neuroinflammation in Alzheimer’s disease. Lancet Neurology, 14, 388–405. doi: 10.1016/S1474-4422(15)70016-5.CrossRefGoogle ScholarPubMed
Holmes, C. (2013). Review: systemic inflammation and Alzheimer’s disease. Neuropathology and Applied Neurobiology, 39, 51–68. doi: 10.1111/nan.2013.39.issue-1.CrossRefGoogle ScholarPubMed
King, E. et al. (2017). Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias. Journal of Neurology, Neurosurgery, and Psychiatry, 89, 339–345. doi: 10.1136/jnnp-2017-317134.CrossRefGoogle ScholarPubMed
King, E. and Thomas, A. (2017). Systemic inflammation in Lewy body diseases: a systematic review. Alzheimer Disease and Associated Disorders, 31, 346–356. doi: 10.1097/WAD.0000000000000211.CrossRefGoogle ScholarPubMed
Koyama, A., O’Brien, J., Weuve, J., Blacker, D., Metti, A. L. and Yaffe, K. (2013). The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: a meta-analysis. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 68, 433–440. doi: 10.1093/gerona/gls187.CrossRefGoogle ScholarPubMed
Lawton, M. P. and Brody, E. M. (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist, 9, 179–186. doi: 10.1093/geront/9.3_Part_1.179.CrossRefGoogle ScholarPubMed
Magaki, S., Mueller, C., Dickson, C. and Kirsch, W. (2007). Increased production of inflammatory cytokines in mild cognitive impairment. Experimental Gerontology, 42, 233–240. doi: 10.1016/j.exger.2006.09.015.CrossRefGoogle ScholarPubMed
Marcos, G. et al. (2016). Conversion to dementia in mild cognitive impairment diagnosed with DSM-5 criteria and with Petersen’s criteria. Acta Psychiatrica Scandinavica, 133, 378–385. doi: 10.1111/acps.12543.CrossRefGoogle ScholarPubMed
McKeith, I. et al. (2007). Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology, 6, 305–313. doi: 10.1016/S1474-4422(07)70057-1.CrossRefGoogle ScholarPubMed
McKeith, I. G. (2002). Dementia with Lewy bodies. British Journal of Psychiatry, 180, 144–147. doi: 10.1192/bjp.180.2.144.CrossRefGoogle ScholarPubMed
McKeith, I. G. et al. (2017). Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology, 89, 88–100. doi: 10.1212/WNL.0000000000004058.CrossRefGoogle ScholarPubMed
McKhann, G. M. et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7, 263–269. doi: 10.1016/j.jalz.2011.03.005.CrossRefGoogle Scholar
Miguel-Alvarez, M. et al. (2015). Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer’s disease: a systematic review and meta-analysis of treatment effect. Drugs Aging, 32, 139–147. doi: 10.1007/s40266-015-0239-z.CrossRefGoogle ScholarPubMed
Miller, M. D. et al. (1992). Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Research, 41, 237–248. doi: 10.1016/0165-1781(92)90005-N.CrossRefGoogle ScholarPubMed
Mioshi, E., Dawson, K., Mitchell, J., Arnold, R. and Hodges, J. R. (2006). The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. International Journal of Geriatric Psychiatry, 21, 1078–1085. doi: 10.1002/(ISSN)1099-1166.CrossRefGoogle ScholarPubMed
Monsonego, A., Maron, R., Zota, V., Selkoe, D. J. and Weiner, H. L. (2001). Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the USA, 98, 10273–10278. doi: 10.1073/pnas.191118298.CrossRefGoogle ScholarPubMed
Motta, M., Imbesi, R., Di Rosa, M., Stivala, F. and Malaguarnera, L. (2007). Altered plasma cytokine levels in Alzheimer’s disease: correlation with the disease progression. Immunology Letters, 114, 46–51. doi: 10.1016/j.imlet.2007.09.002.CrossRefGoogle ScholarPubMed
O’Brien, J. T. et al. (2009). Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. British Journal of Psychiatry, 194, 34–39. doi: 10.1192/bjp.bp.108.052050.CrossRefGoogle ScholarPubMed
Reale, M. et al. (2009). Peripheral cytokines profile in Parkinson’s disease. Brain, Behavior, and Immunity, 23, 55–63. doi: 10.1016/j.bbi.2008.07.003.CrossRefGoogle ScholarPubMed
Song, D. K., Im, Y. B., Jung, J. S., Cho, J., Suh, H. W. and Kim, Y. H. (2001). Central beta-amyloid peptide-induced peripheral interleukin-6 responses in mice. Journal of Neurochemistry, 76, 1326–1335. doi: 10.1046/j.1471-4159.2001.00121.x.CrossRefGoogle ScholarPubMed
Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J. and Herrmann, N. (2010). A meta-analysis of cytokines in Alzheimer’s disease. Biological Psychiatry, 68, 930–941. doi: 10.1016/j.biopsych.2010.06.012.CrossRefGoogle ScholarPubMed
Thomas, A. J. et al. (2018). Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychological Medicine (in press). doi: 10.1017/S0033291718000995.Google ScholarPubMed
Verghese, J., Crystal, H. A., Dickson, D. W. and Lipton, R. B. (1999). Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology, 53, 1974–1974. doi: 10.1212/WNL.53.9.1974.CrossRefGoogle Scholar
Walker, Z. et al. (2016). Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. Neurology, 87, 1045–1051. doi: 10.1212/WNL.0000000000003076.CrossRefGoogle ScholarPubMed